Umeclidinium 62.5mcg; per inhalation; dry pwd for oral inhalation; contains lactose. Incruse Ellipta should be stored at room temperature between 68°-77° F (20°-25° C); excursions permitted from ...
LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse™ Ellipta ® (umeclidinium) as an ...
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Incruse™ Ellipta™ (umeclidinium, as umeclidinium bromide) has received market authorisation in Canada for the long-term once-daily maintenance ...
GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD GlaxoSmithKline plc ...
Incruse Ellipta Inhaler Approved for COPD GlaxoSmithKline announced that the FDA has approved Incruse Ellipta (umeclidinium) inhaler for the long-term, once-daily, maintenance treatment of airflow ...
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from ...
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from two head-to-head studies directly comparing the efficacy and safety of Incruse® Ellipta® (umeclidinium) to two available ...
GlaxoSmithKline’s chronic obstructive pulmonary disorder bronchodilator Incruse Ellipta 55mcg (umeclidinium) has been recommended for National Health Service use by the All Wales Medicines Strategy ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Do not use if you have ever had an allergic reaction to INCRUSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results